Emapalumab
- Generic Name
- Emapalumab
- Brand Names
- Gamifant
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1709815-23-5
- Unique Ingredient Identifier
- 3S252O2Z4X
- Background
Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018. The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough therapy. As well, emapalumab w...
- Indication
Emapalumab is indicated for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy.
...
- Associated Conditions
- Progressive, refractory, primary intolerance with conventional therapy, recurrent Hemophagocytic Lymphohistiocytosis
- Associated Therapies
- -
Swedish Orphan Biovitrum Has Built a Narrow Moat Around Hematology and Immunology Products
Since 2016, Sobi has expanded from a European specialty pharmaceutical firm to include US markets and new therapeutic areas in immunology and hematology through successful drug launches and acquisitions, warranting a narrow moat rating.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath